Overactive Bladder Treatment Market Sketch
Market Research Future (MRFR) predicts that the global overactive bladder treatment -market is anticipated to grow with a CAGR of 3.1% in the assessment period of 2017-2023.
Increase in prevalence of overactive bladder in the geriatric population is urging the need for effective treatment. Overactive bladder can exist as a comorbid condition in cases of multiple sclerosis, stroke, and Parkinson disease.
Free Sample PDF Available Here!! https://www.marketresearchfuture.com/sample_request/6248
These are creating immense scope for the pharmaceuticals in the healthcare industry to invest in research and development activities for manufacturing more effective medication and advanced diagnostic techniques. These factors are the market propellers for the upcoming years. Affordable treatment for overactive bladder is another reason anticipated, for market growth. Lack of awareness and slacken medical infrastructure in under-developed regions are the possible reasons that can hinder the global overactive bladder treatment growth.
Overactive Bladder Treatment Market Studied By Top Key Players
- Astellas Pharma
- Pfizer
- Teva Pharmaceutical Industries Ltd
- Sanofi S. A
- Aurobindo Pharma Limited
- Allergan
- Mylan N.V.
- Endo International Plc
- Hisamitsu Pharmaceutical Co.
- Johnson & Johnson
- Intas Pharmaceuticals Ltd.
- Apotex
- Macleods Pharmaceuticals
- Medtronic PLC
- Cogentix Medical
others are the prime companies existing in the overactive bladder treatment market, globally.
Overactive Bladder Treatment Market Segmental Overview
MRFR has segmented the global overactive bladder treatment market study by pharmacotherapy, non-pharmacological treatment, and disease.
Based on pharmacotherapy, the global overactive bladder treatment market has been segmented into anticholinergics, botox, mirabegron, neurostimulation, and others. The anticholinergics segment has been narrowed down to solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
Based on non-pharmacological treatment, the global overactive bladder treatment market has been segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
Based on disease, the global overactive bladder treatment market has been segmented into idiopathic overactive bladder and neurogenic overactive bladder. The neurogenic overactive bladder segment has been further classified the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Overactive Bladder Treatment Market Regional Analysis
The regional segmental analysis of the overactive bladder treatment by MRFR includes America, Europe, Asia-Pacific, and the Middle East and Africa.
The overactive bladder treatment market in the Americas is sub-segmented into North America and South America. The North America segment is further classified as the US and Canada. The North American region is expected to dominate the market, globally, in the forecast period of 2018-2023 owing to availability of healthcare insurances like Medicare.
The European market is expected to hold the second largest market share. Increase in instanced of overactive bladder and reimbursement policies like the UK’s National Institutes for Health and Care Excellence (NICE) that provides reimbursement for the Botox therapy are major factors expected to amplify the regional overactive bladder treatment market in the forthcoming year.
Emerging economies like India, China, Japan in the Asia Pacific region investing in the medical advancements for availing effective overactive bladder treatment to patients is anticipated to propel the market growth in the APAC region.
Lack of medical awareness and medical infrastructure in the Middle East and African region can retard the regional overactive bladder treatment market.
Industry Update
January 2019: In the Washington University School of Medicine, researchers announced their latest invention, an implantable device that allows overactive bladder treatment without the use of electronic stimulators or medications. January 2019: Researchers from the University of Illinois, Northwestern University, US and the University of Washington announced the latest innovation which is a compact implantable device. This device detects overactivity in the bladder and reduces the urge of urination using bio-integrated LEDs.
OBTAIN RESEARCH REPORT DETAILS WITH TOC @ https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248